-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On December 31, the traditional Chinese medicine sector changed again.
In terms of individual stocks, Northeast Pharmaceuticals, Foci Pharmaceuticals, and Yibo Pharmaceuticals and Lingrui Pharmaceuticals followed suit
.
2 individual stocks daily limit Northeast Pharmaceuticals opened at 5.
76 yuan today, and as of 10:05, the stock rose 10.
09% to 6.
22 yuan, closing the upper limit
.
The current turnover is 104 million, and the turnover rate is 1.
30%
.
The stock has risen by the limit once in the past year
.
For the reasons for this change, the analysis believes that the company's main business is the production and sales of chemical raw materials and pharmaceutical preparations, the wholesale and retail of pharmaceutical products, and the production and sales of biological preparations
.
At present, Northeast Pharmaceutical mainly produces vitamin series medicines, anti-infective system medicines, obstetrics and gynecology system medicines, digestive system medicines, urinary system medicines, anti-AIDS medicines, cardiovascular and cerebrovascular medicines, anesthesia series medicines, biological diagnosis series, large A series of high-quality products in the health field, more than 400 kinds of chemical raw materials, pharmaceutical intermediates and preparation products, leading products are exported to more than 100 countries and regions
.
In the first three quarters of 2021, Northeast Pharmaceutical's performance has improved significantly, achieving operating income of 6.
105 billion yuan, a year-on-year increase of 11.
27%; net profit of 25.
4976 million yuan, a year-on-year increase of 3040.
49%
.
Among them, in the third quarter, the company's revenue and net profit increased by 18.
83% and 39.
22% year-on-year respectively
.
Foci Pharmaceuticals opened at 9.
12 yuan today.
As of 10:05, the stock rose 9.
97% to 10.
04 yuan, also closing the price limit
.
The current turnover is 175 million, and the turnover rate is 3.
53%
.
Foci Pharmaceutical has daily limit 3 times in the past year
.
Behind the daily limit, the analysis pointed out that the company's main business is the research and development, manufacturing and sales of Chinese patent medicines and big health products, as well as the cultivation, processing and sales of Chinese medicinal materials
.
The company's main products include Liuwei Dihuang Pills, Xiaoyao Pills, Xiangsha Yangwei Pills, Ginseng Guben Huanshao Pills and other series of proprietary Chinese medicines, as well as Ejiao, Ejiao cakes and other large health products
.
In addition to the above two stocks, there are many more stocks
.
For example, as of 10:05, Yibo Pharmaceuticals rose 7.
32% to 8.
21 yuan; Lingrui Pharmaceuticals rose 7.
58% to 15.
90 yuan
.
It can be found that most of the obvious stock price changes today are companies whose main business is engaged in related traditional Chinese medicine
.
According to the analysis, due to strong policy support, the number of approved innovative traditional Chinese medicines has reached 11 since 2021, hitting a new high in the past five years
.
Affected by this news, related sectors continued to be strong, and in this context, Chinese medicine stocks ushered in a major reversal
.
Looking forward to the future market, the industry generally believes that the traditional Chinese medicine industry is expected to usher in new opportunities
.
Among them, Sinolink Securities pointed out that the relevant policies have created a better growth environment for the traditional Chinese medicine industry
.
Centralized procurement is conducive to the admission of traditional Chinese medicine to hospitals and broadening the channels for volume reduction
.
In addition, with the stricter supervision of Chinese herbal medicines and the rise in prices, it will increase the cost pressure of Chinese medicine companies
.
Due to its obvious advantages in the OTC category, traditional Chinese medicine's main sales channels are concentrated on the retail side and self-operated rather than self-operated, and only a small number of them are included in the list of centralized purchases.
Driven by both market demand and the emphasis on the pharmacy side, they have higher prices.
maintenance capability
.
At the same time, with the intensification of population aging, the base of chronic disease patients continues to expand, and the rigid demand for traditional Chinese medicine continues to grow
.
In addition, residents' consumption structure has been upgraded, their disposable income has increased, their awareness of health management has been greatly improved due to the impact of the epidemic, and residents' demand for disease prevention and treatment has increased
.
In general, opportunities and challenges coexist in traditional Chinese medicine, and there is a broad space for innovation and development and consumption upgrading in the future
.
In terms of individual stocks, Northeast Pharmaceuticals, Foci Pharmaceuticals, and Yibo Pharmaceuticals and Lingrui Pharmaceuticals followed suit
.
2 individual stocks daily limit Northeast Pharmaceuticals opened at 5.
76 yuan today, and as of 10:05, the stock rose 10.
09% to 6.
22 yuan, closing the upper limit
.
The current turnover is 104 million, and the turnover rate is 1.
30%
.
The stock has risen by the limit once in the past year
.
For the reasons for this change, the analysis believes that the company's main business is the production and sales of chemical raw materials and pharmaceutical preparations, the wholesale and retail of pharmaceutical products, and the production and sales of biological preparations
.
At present, Northeast Pharmaceutical mainly produces vitamin series medicines, anti-infective system medicines, obstetrics and gynecology system medicines, digestive system medicines, urinary system medicines, anti-AIDS medicines, cardiovascular and cerebrovascular medicines, anesthesia series medicines, biological diagnosis series, large A series of high-quality products in the health field, more than 400 kinds of chemical raw materials, pharmaceutical intermediates and preparation products, leading products are exported to more than 100 countries and regions
.
In the first three quarters of 2021, Northeast Pharmaceutical's performance has improved significantly, achieving operating income of 6.
105 billion yuan, a year-on-year increase of 11.
27%; net profit of 25.
4976 million yuan, a year-on-year increase of 3040.
49%
.
Among them, in the third quarter, the company's revenue and net profit increased by 18.
83% and 39.
22% year-on-year respectively
.
Foci Pharmaceuticals opened at 9.
12 yuan today.
As of 10:05, the stock rose 9.
97% to 10.
04 yuan, also closing the price limit
.
The current turnover is 175 million, and the turnover rate is 3.
53%
.
Foci Pharmaceutical has daily limit 3 times in the past year
.
Behind the daily limit, the analysis pointed out that the company's main business is the research and development, manufacturing and sales of Chinese patent medicines and big health products, as well as the cultivation, processing and sales of Chinese medicinal materials
.
The company's main products include Liuwei Dihuang Pills, Xiaoyao Pills, Xiangsha Yangwei Pills, Ginseng Guben Huanshao Pills and other series of proprietary Chinese medicines, as well as Ejiao, Ejiao cakes and other large health products
.
In addition to the above two stocks, there are many more stocks
.
For example, as of 10:05, Yibo Pharmaceuticals rose 7.
32% to 8.
21 yuan; Lingrui Pharmaceuticals rose 7.
58% to 15.
90 yuan
.
It can be found that most of the obvious stock price changes today are companies whose main business is engaged in related traditional Chinese medicine
.
According to the analysis, due to strong policy support, the number of approved innovative traditional Chinese medicines has reached 11 since 2021, hitting a new high in the past five years
.
Affected by this news, related sectors continued to be strong, and in this context, Chinese medicine stocks ushered in a major reversal
.
Looking forward to the future market, the industry generally believes that the traditional Chinese medicine industry is expected to usher in new opportunities
.
Among them, Sinolink Securities pointed out that the relevant policies have created a better growth environment for the traditional Chinese medicine industry
.
Centralized procurement is conducive to the admission of traditional Chinese medicine to hospitals and broadening the channels for volume reduction
.
In addition, with the stricter supervision of Chinese herbal medicines and the rise in prices, it will increase the cost pressure of Chinese medicine companies
.
Due to its obvious advantages in the OTC category, traditional Chinese medicine's main sales channels are concentrated on the retail side and self-operated rather than self-operated, and only a small number of them are included in the list of centralized purchases.
Driven by both market demand and the emphasis on the pharmacy side, they have higher prices.
maintenance capability
.
At the same time, with the intensification of population aging, the base of chronic disease patients continues to expand, and the rigid demand for traditional Chinese medicine continues to grow
.
In addition, residents' consumption structure has been upgraded, their disposable income has increased, their awareness of health management has been greatly improved due to the impact of the epidemic, and residents' demand for disease prevention and treatment has increased
.
In general, opportunities and challenges coexist in traditional Chinese medicine, and there is a broad space for innovation and development and consumption upgrading in the future
.
